Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay W Carlson

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cancer|April 25, 2003
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinomaJohn H Farley, Kimberly W Hickey, Jay W Carlson, et al.
Gynecologic Oncology|September 10, 2002
Modified technique for urinary diversion with incontinent conduitsWilliam E Winter, Thomas C Krivak, G Larry Maxwell, et al.
Gynecologic Oncology|August 7, 2004
Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|May 17, 2008
A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group studyJay W Carlson, James Kauderer, Joan L Walker, et al.
Gynecologic Oncology|October 8, 2003
Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpusWilliam E Winter, Jeffrey D Seidman, Thomas C Krivak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|April 26, 2003
Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancerEdward R Kost, Kevin L Hall, Jeffrey F Hines, et al.
Gynecologic Oncology|December 28, 2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyUrsula A Matulonis, Michael W Sill, Vicky Makker, et al.
Gynecologic Oncology|December 16, 2019
GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patientsJay W Carlson, James Kauderer, Alan Hutson, et al.
Gynecologic Oncology|May 29, 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancerCarol Aghajanian, Virginia Filiaci, Don S Dizon, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer|April 25, 2003
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinomaJohn H Farley, Kimberly W Hickey, Jay W Carlson, et al.
Gynecologic Oncology|September 10, 2002
Modified technique for urinary diversion with incontinent conduitsWilliam E Winter, Thomas C Krivak, G Larry Maxwell, et al.
Gynecologic Oncology|August 7, 2004
Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|May 17, 2008
A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group studyJay W Carlson, James Kauderer, Joan L Walker, et al.
Gynecologic Oncology|October 8, 2003
Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpusWilliam E Winter, Jeffrey D Seidman, Thomas C Krivak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|April 26, 2003
Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancerEdward R Kost, Kevin L Hall, Jeffrey F Hines, et al.
Gynecologic Oncology|December 28, 2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyUrsula A Matulonis, Michael W Sill, Vicky Makker, et al.
Gynecologic Oncology|December 16, 2019
GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patientsJay W Carlson, James Kauderer, Alan Hutson, et al.
Gynecologic Oncology|May 29, 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancerCarol Aghajanian, Virginia Filiaci, Don S Dizon, et al.
Pageof 3